05:26:52 EST Wed 08 Feb 2023
Enter Symbol
or Name

Login ID:
Empower Clinics Inc
Symbol EPW
Shares Issued 345,760,021
Close 2022-11-25 C$ 0.04
Recent Sedar Documents

Empower loses $457,066 (U.S.) from continuing ops in Q3

2022-11-28 11:36 ET - News Release

Mr. Steven McAuley reports


Empower Clinics Inc. has filed its unaudited condensed interim consolidated financial statements and related management's discussion and analysis for the three and nine months ended Sept. 30, 2022, both of which are available at SEDAR. All financial information in this press release is reported in United States dollars, unless otherwise indicated.

We are pleased to deliver substantial revenue growth, with revenues almost tripling this quarter on a year over year basis. This is the second consecutive quarter that we've maintained strong revenue growth when compared to last year", said Steven McAuley, Chairman and CEO of Empower Clinics. "We realized strong returns on our investment to launch fully certified COVID-19 testing solutions and centers in the Vancouver waterfront area. MediSure Canada continues to experience healthy sales growth across its entire suite of medical devices and at-home testing solutions, including the immediate adoption of products launched just this year. MediSure Labs now has new leadership with a proven track record to help realize its revenue potential. The Medi-Collective is successfully recruiting doctors and adding specialty services like cardiology and dermatology. Recognizing macro-economic challenges, we will operate as efficiently as possible and looking forward to 2023, we will focus our growth efforts on U.S. healthcare opportunities, in large markets and sectors that we are already invested in."

Q3 2022 HighlightsTotal revenues from continuing operations of $1,573,809 for Q3 2022 compared to revenues of $405,707 for Q3 2021, representing a 288% increase year over year. The increase in revenue is primarily attributed to the launch of Empower Clinic's COVID-19 testing clinics for cruise ship passengers and increased sales from MediSure.Gross margin from continuing operations was 59% for Q3 2022, compared to 95% in Q3 2021, representing 37% decrease.Net loss from continuing operations was $457,066 or $0.00 per share compared to a net loss from continuing operations of $1,711,659 or $0.01 per share for Q3 2021. The net loss for current period was primarily driven by an increase in operating expenses related to Empower Clinic's COVID-19 testing site and ongoing operations in Medi-Collective clinics.Cash as at September 30, 2022 of $469,712, compared to cash of $866,170 at December 31, 2021.Cash used in operating activities from continuing operations was $94,075 for Q3 2022, compared to $1,247,009 for Q3 2021.

Financial Performance

As part of total revenues, revenues from the Health & Wellness segment for Q3 2022 were $284,001 compared to Q3 2021 revenues of $244,752. This increase over the prior year period is attributable to higher revenues from Medi-Collective's clinics.

Diagnostics & Technology revenue includes the sale of MediSure products and COVID-19 testing conducted by Kai Medical Laboratory and Empower Clinics. Diagnostics & Technology revenue for Q3 2022 were $1,289,808 with 58% attributable to COVID-19 testing, compared to Q3 2021 revenues of $160,955. This increase over the prior year period is attributable to the launch of COVID-19 testing solutions for cruise travel passengers in Vancouver, Canada.

Direct expenses excluding depreciation and amortization for Q3 2022 were $642,187 compared to Q3 2021 direct clinic expenses of $18,377. The increase in direct expense was due to the increased direct personnel costs related to the launch of COVID-19 testing in Vancouver, Canada.

Loss from operations for Q3 2022 was $906,315 compared to Q3 2021 of $601,979. This increase in loss from prior year period is attributed to additional expenses related to insurance, travel and recruitment costs within clinic operating expenses.

Net loss from continuing operations for Q3 2022 was $457,066, compared to net loss in Q3 2021 of $1,711,659. In Q3 2021, the Company recognized an aggregate of $4,342,373 in impairment charges, while no such impairment was recognized in Q3 2022. This was offset by a gain on change in fair value of the warrant liability of $3,131,006 in Q3 2021 compared to a lower gain in Q3 2022 of $354,582 and the addition of a gain on change in fair value of a conversion feature associated with convertible debentures issued by the Company.

Adjusted EBITDA is a non-GAAP financial measure that is calculated as net loss from continuing operations before depreciation and amortization, interest, accretion, share-based compensation, and changes in the fair value of derivative liabilities. Adjusted EBITDA loss in Q3 2022 was $775,927compared to $28,732 in Q3 2021. Adjusted EBITDA is a metric used by management to monitor the Company's revenues compared to its cash operating costs in an effort to trend toward improved profitability.

During Q3 2022, the Company used $94,075 of cash in the operating activities from continuing operations. The Company invested cash of $3,103 for the purchase of furniture and equipment and used $236,098 of cash in financing activities for lease payments and repayments of loans and notes payable.

Please refer to the Company's condensed interim consolidated financial statements, related notes and accompanying Management Discussion and Analysis for a full review of the operations.

About Empower

Empower is an integrated healthcare company that provides body and mind wellness for patients through its clinics, with digital and telemedicine care, and world-class medical diagnostics laboratories. Supported by an experienced leadership team, Empower is aggressively growing its clinical and digital presence across North America. Our Health & Wellness and Diagnostics & Technology business units are positioned to positively impact the integrated health of our patients, while simultaneously providing long term value for our shareholders.

We seek Safe Harbor.

© 2023 Canjex Publishing Ltd. All rights reserved.